Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Philip Weighner

Internal Medicine Grand Rapids, MI Medical Doctor

NPI 1710945480 CMS profile 305145

1000 E Paris Ave Se, Suite 260, Grand Rapids, MI 49546

Open in the dashboard

General payments

$5,408

344 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Philip Weighner of Grand Rapids, MI is reported in the CMS Open Payments database as having received $5,408 across 344 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $31 2
2022 General $2,174 133
2021 General $944 52
2020 General $353 25
2019 General $1,906 132

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Philip Weighner
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Philip Weighner were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Philip Weighner Internal Medicine median Middle half National median
2019 $1,906 $159 $48–$570 $163
2020 $353 $119 $33–$402 $114
2021 $944 $135 $37–$521 $132
2022 $2,174 $141 $42–$496 $149
2023 $31 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Novo Nordisk Inc $820 46 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $617 39 payments
  3. AstraZeneca Pharmaceuticals LP $491 30 payments
  4. AbbVie, Inc. $435 29 payments
  5. Pfizer Inc. $398 28 payments
  6. Amarin Pharma Inc. $336 30 payments
  7. Lilly USA, LLC $314 26 payments
  8. Janssen Pharmaceuticals, Inc $253 20 payments
  9. Astellas Pharma US Inc $222 7 payments
  10. Novartis Pharmaceuticals Corporation $176 11 payments
  11. Other $1,347 78 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $5,159 322 payments
  2. Education $248 22 payments
Products named General payments · program years 2019–2023
  1. Ozempic $563 29 payments
  2. RYBELSUS $464 24 payments
  3. FARXIGA $361 20 payments
  4. SPIRIVA RESPIMAT $334 21 payments
  5. STIOLTO RESPIMAT $271 17 payments
  6. JARDIANCE $253 13 payments
  7. XARELTO $231 17 payments
  8. Vascepa $229 25 payments
  9. TRULICITY $193 16 payments
  10. VRAYLAR $189 12 payments
  11. Other $5,012 319 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

344 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record